Creative Biolabs has announced a significant expansion of its advanced single-cell multi-omics and RNA sequencing solutions, a move that promises to accelerate biomedical discovery by providing researchers with more powerful tools to dissect cellular heterogeneity at unprecedented resolution. The upgraded suite of services is designed to meet the growing demand for high-resolution cellular profiling, offering end-to-end workflows that span from single-cell transcriptome profiling to integrated multimodal and multi-omics analyses.
As life science research increasingly shifts from bulk tissue profiling to single-cell resolution, the ability to identify rare cell subpopulations, characterize complex tumor microenvironments, and trace cell lineage trajectories has become essential. Creative Biolabs now delivers robust, high-throughput single-cell RNA sequencing services that offer high sensitivity and coverage across thousands of individual cells, providing high-resolution transcriptomic insights from diverse fresh biological specimens.
A key challenge in single-cell research has been the processing of complex, fibrous, or biobanked archival samples. To address this, the platform features specialized single-nucleus RNA sequencing (snRNA-seq) capabilities. For tissues where traditional single-cell dissociation can cause cell damage, dissociation-induced stress responses, or selective loss of fragile cell types—such as human brain, myocardium, or flash-frozen clinical biopsies—Creative Biolabs provides an optimized single-cell nuclei RNA sequencing service. By isolating intact nuclei, this approach bypasses harsh enzymatic dissociation while minimizing artifacts and retaining informative nuclear RNA profiles, thereby dramatically expanding the scope of clinical translational research.
Recognizing that cellular identity is orchestrated across multiple regulatory layers, Creative Biolabs goes beyond single-dimensional analysis by advancing its high-throughput single-cell multi-omics service. This integrated platform allows the simultaneous interrogation of genomic variations, epigenomic landscapes (e.g., chromatin accessibility), cell surface proteomics (CITE-seq), and transcriptomes within identical single cells. By directly linking epigenetic regulation and genomic alterations to gene expression readouts, the service enables researchers to construct multi-dimensional cellular atlases and uncover novel therapeutic targets with unprecedented biological clarity.
"Understanding biology at single-cell and single-nucleus resolution is no longer a luxury—it is fundamental to precision medicine and biomarker discovery," said a senior scientist at Creative Biolabs. "Our goal is to provide researchers with a seamless, modular analytical ecosystem that transforms difficult biological samples into reliable, high-dimensional datasets with rigorous bioinformatics support."
The implications of this expansion are far-reaching. By offering a comprehensive suite of single-cell solutions, Creative Biolabs is empowering global researchers across oncology, immunology, and neuroscience to delve deeper into the complexities of human disease. The ability to simultaneously analyze multiple omics layers in individual cells can reveal novel insights into disease mechanisms, identify new biomarkers, and accelerate the development of targeted therapies. Supported by advanced microfluidics technologies, stringent quality control benchmarks, and tailored bioinformatics pipelines, Creative Biolabs continues to partner with academic and biopharmaceutical research teams worldwide. For more information about Creative Biolabs and its full suite of single-cell analytical solutions, please visit https://singlecell.creative-biolabs.com/.
